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Abstract We have sought to determine the influence of the car- 
bohydrate moiety of the antitumour antibiotic hleomycin on the 
sequence-specific cleavage of DNA. Both bleomycin A2 and de- 
glycobleomycin A2 produce different cleavage patterns with DNA 
in which the 2-amino group has been removed from guanine, 
added to adenine, or both, as well as on a designed DNA fragment 
containing a few defined cleavage sites. Although each drug 
cleaves DNA primarily at GpT and GpC sites, the cleavage at 
these sites is frequently found to be stronger with deglycobleomy- 
cin compared with bleomycin A 2. Conversely, in most cases the 
cleavage at secondary sites, in particular at ApT steps, is signif- 
icantly reduced or even abolished with deglycobleomycin. The 
results indicate that the gulose-mannose moiety of bleomycin A2 
plays a significant role in the recognition of preferred nucleotide 
sequences and confirm the view that both secondary structure and 
interaction with guanine are involved in determining sequence- 
specific cleavage of DNA by bleomycin. 
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to DNA. In addition, NMR studies suggest hat the carbohy- 
drate portion could contribute to the interaction since intermol- 
ecular NOEs between the gulose and the central thymidine in 
the sequence d(CGCTAGCG)2 have been detected [12]. We 
have explored this idea by comparing the patterns of cleavage 
by bleomycin A2 and deglycobleomycin A2. We report that the 
sugar moiety of bleomycin is not mandatory for cutting at 
primary GpT and GpC sites but it plays a decisive role in 
cutting at secondary sites, particularly ApT. 
2. Materials and methods 
2.1. Bleomycin A2 and deglycobleomycin 
A pure sample of bleomycin Az was obtained from Roger-Bellon 
Laboratories (Neuilly-sur-Seine, France). The gulose-mannose moiety 
of bleomycin A2 was specifically cleaved by HF solvolysis according to 
a published protocol [13]. Deglycobleomycin A2 was purified by HPLC 
and the integrity of the deglycosylated antibiotic was checked by 
[~H]NMR and HR-FAB mass spectrometry. Stock solutions were pre- 
pared in 10 mM Tris-HCl buffer containing 10 mM NaC1, pH 7.0, 
divided into 250-gtM aliquots and stored at -20°C. 
I. Introduction 
The bleomycins, used in cancer chemotherapy for more than 
20 years, cleave nucleic acids sequence-specifically in the pres- 
ence of oxygen and certain metal ions [1,2]. The structure of 
bleomycin A2 (Fig. 1) - -  the major component of the clinical 
formulation - -  is commonly divided into three functional do- 
mains: (i) the bithiazole and sulphonium side-chain which pro- 
vide a DNA-binding element [1-3], (ii) the pseudopeptide por- 
tion which acts as a metal chelating/oxygen activation domain 
[1,2] and (iii) the carbohydrate moiety which may help to com- 
plex the metal, stabilise the reactive oxygenated species [4-6] 
and facilitate penetration i to cells [7]. However, the exact role 
of the gulose-mannose disaccharide remains uncertain. 
Although the bithiazole contributes significantly to the inter- 
action with DNA, different studies suggest hat it is the pseu- 
dopeptide moiety which is mainly responsible for sequence 
recognition [8-10]. Two recent models based on interaction 
with oligonucleotides [11,12] differ as regards the mode of bind- 
ing of the bithiazole unit but both confirm that the pseudopep- 
tide constitutes a prime element for sequence-specific binding 
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Abbreviations." bp, base pair(s). 
2.2. DNA j?agments 
The 48-bp AT-rich fragment was cloned between the HindllI and 
BamHI sites of the pUC12 vector to afford the plasmid construct pCB2 
[141. Four additional restriction fragments were used to investigate 
cleavage of DNA by bleomycin and deglycobleomycin: (i) a 178-bp 
EcoRI-PvulI fragment from pUC12, (ii) a 117-bp fragment and (iii) a 
265-bp fragment both cut out of plasmid pBS with EcoRI and PvulI, 
and (iv) the 160-bp tyrT(A93) fragment cut out of plasmid pKMp27. 
The four different 160-bp DNA fragments containing either natural 
bases or inosine residues in place of guanines or 2,6-diaminopurine 
residues (abbreviated D within a sequence for clarity) in place of ade- 
nines or both I and DAP residues were synthesized by PCR amplifica- 
tion as described recently [15,16]. Restriction fragments were 3'-end- 
labelled with [c~-32P]dATP in the presence of avian myeloblastosis virus 
reverse transcriptase. The purified PCR products were 5'-end-labelled 
with [7-3ZP]ATP in the presence of T4 polynucleotide kinase according 
to a standard procedure for labelling blunt-ended DNA fragments. 
After completion of the labelling reaction, the DNA was again purified 
by electrophoresis on a 6% polyacrylamide g l. Finally, the radioactive 
DNA was resuspended in 10 mM Tris-HCl, pH 7.0, buffer containing 
10 mM NaC1. 
2.3. Cleavage of DNA by the bleomycin- and deglycobleomyein-Fe n 
complexes 
In a typical experiment, the freshly prepared bleomycin Fe ~ complex 
(4 ¢tl) was added to 6 pl of [32p]-end-labelled DNA (~ 1 nM) in 10 mM 
Tris-HCl buffer, pH 7.0, containing 10 mM NaC1. The bleomycin-Fe II 
complex consisted of 2 pl of a 5-¢tM solution of bleomycin A2 mixed 
with 2 gtl of 5/~M Fe(NH4)2(SO4) 2 "6H20 just prior to the experiment. 
After 1 min incubation at room temperature, the cleavage reaction was 
stopped by freezing. Samples were lyophilized, resuspended in 50/.tl of 
water and lyophilized again. With deglycobleomycin, the digestion time 
was 2 min to compensate for the slightly lower efficiency of DNA 
cleavage by the deglycobleomycin-Fe H complex compared with the 
bleomycin-Fe" complex. The cleavage products were resuspended in 
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Fig. 1. Structures of bleomycin A~ and deglycobleomycin A2. 
/tl of formamide-dye solution and resolved on a denaturing poly- 
tcrylamide gel as described below. 
?.4. Electrophoresis and quantitation by storage phosphor-imaging 
DNA-cleavage products were resolved by polyacrylamide gelelectro- 
phoresis under denaturing conditions (0.3 mm thick, 8% acrylamide 
:ontaining 8 M urea). After the electrophoresis (-2.5 h at 60 W, 1600 
V in TBE buffer, BRL sequencer model $2), gels were soaked in 10% 
acetic acid for 15 rain, transferred to Whatman 3MM paper, dried 
under vacuum at 80°C and examined by autoradiography using either 
a phosphorimager or X-ray films (Fuji R-X) exposed at -70°C with an 
intensifying screen usually for 24 h. For quantitative analysis, a Molec- 
ular Dynamics 425E Phosphorlmager was used to collect data from 
storage screens exposed to the dried gels overnight at room tempera- 
ture. Base line-corrected scans were analysed by integrating all the 
densities between two selected boundaries using ImageQuant Version 
3.3 software. Each resolved band was assigned to a particular bond 
within the DNA fragment by comparison of its position relative to 
sequencing standards (G or G + A tracks), 
3. Results and discussion 
Recently, we showed that the 2-amino group of guanine 
directs sequence-specific cleavage of DNA by bleomycin [17]. 
Cutting of DNA by deglycobleomycin also depends on the 
location of that group. Fig. 2 shows comparative cleavage pat- 
terns on a series of homologous tyrT(A93) DNA molecules 
containing inosine and/or 2,6-diaminopurine residues in place 
of guanosine and/or adenine residues, respectively. With both 
bleomycin and its deglycosylated analogue, the cleavage pat- 
tern varies considerably depending whether the purine 2-amino 
group is present on guanine, transferred toadenine, present on 
both or missing altogether. Furthermore, the intensity of strand 
scission at a given bond frequently differs for the two drugs: a 
site of strong cleavage with bleomycin sometimes corresponds 
to a weak site for deglycobleomycin or vice versa (Fig. 4). The 
chief outcome is that with normal DNA most, but not all, GpC 
and GpT__ steps (the reactive nucleotide is underlined) appear 
Fig. 2. Cleavage by the Fe jl complex of Neomycin A2 and deglycobleo- 
mycin (1 ,uM each) of 5'-end-labelled tyrT(A93) DNA species contain- 
ing natural or modified nucleotides. 
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Fig. 3. Cleavage by the Fe n complex of bleomycin A2 and deglycobleo- 
mycin (1/JM each) of a 170-mer DNA fragment containing the indi- 
cated insert. 
more susceptible to cleavage by deglycobleomycin compared 
with bleomycin whereas cleavage at secondary sites is fre- 
quently reduced with the deglycosylated derivative (e.g. ApT 
109 and GpA 104). The results with the doubly substituted 
I + DAP DNA are totally consistent with this conclusion since 
cleavage at DpC and DpT sites is stronger with deglycobleomy- 
cin than with bleomycin A2 (steps 59, 89, 109 and 125) whereas 
cleavage at IpC or IpT remains weak or is even abolished (steps 
94, 117 and 137). 
We confirmed this observation using other DNA fragments, 
including a designed sequence containing only three GpT sites 
flanked by (A - T), repeats. As shown in Figs. 3 and 4, bleomy- 
cin cuts efficiently at the GpT steps as well as within the adja- 
cent (A • T), tract [18] whereas deglycobleomycin uts almost 
exclusively at GpT. Altogether, these xperiments e tablish that 
removal of the carbohydrate moiety of bleomycin results in 
stronger cleavage at GpPyr sites accompanied by diminished 
cutting at ApPyr sequences. 
Experiments with the singly inosine-substituted DNA show 
that the 2-amino group of guanine is not mandatory for cleav- 
age by either bleomycin or deglycobleomycin: strong cutting is 
still observed espite all purines lacking a 2-amino group, sug- 
gesting that the sequence recognition by both agents depends 
as much on the secondary structure as on the primary sequence 
per se. Indeed, unlike what is observed with normal DNA, 
strong cleavage can be detected at certain ApT sites in I-DNA 
(e.g. positions 89 and 109) although A • T bp have not been 
altered in this polynucleotide. With the DAP-DNA, as ex- 
pected, cleavage can occur at both GpPyr and DpPyr steps 
revealing that the interaction of either drug with the purine 
2-amino group is sufficient (but not necessary) to create new 
cleavage sites. 
Conclusion: Evidently, the carbohydrate moiety ofbleomycin 
affects its recognition of particular nucleotide sequences. More 
specifically, the fact that bleomycin and its deglycosylated ana- 
logue respond ifferently to the location of the purine 2-amino 
group in DNA raises the possibility that the gulose-mannose 
portion of the antibiotic influences recognition via the minor 
groove width. The transfer of the 2-amino group from guanine 
to adenine residues ignificantly modulates the width of the 
minor groove in DNA as judged from experiments with the 
conformation-sensitive probes DNase I and uranyl nitrate [16]. 
Our results reinforce the view that sequence-specific cleavage 
of DNA by bleomycin is the result of a direct recognition of 
the guanine 2-amino group coupled with indirect recognition 
of a suitable minor groove width [1,12,17]. Whereas the carbo- 
hydrate domain of bleomycin apparently contributes little to 
primary sequence recognition (digital read-out), it seems to 
contribute noticeably to the DNA-structure recognition (ana- 
logue read-out). In this regard, bleomycin behaves like other 
antibiotics equipped with carbohydrate substituents, uch as 
calicheamicin and chromomycin [19]. 
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Fig. 4. Comparison of the susceptibility of normal and modified tyrT(A93) DNA (a-d) and the AT-rich insert sequence CB2 (e) to cleavage by 
bleomycin and deglycobleomycin. The relative cleavage intensity at a given bond was measured as a fraction of the total cleavage of all the 
phosphodiester bonds within the sequence. 
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